文献速递慢性静脉疾病

亚洲多中心VenaSeal真实世界上市后评估:氰基丙烯酸酯静脉消融早期疗效与安全性

Early results of an Asian prospective multicenter VenaSeal real-world postmarket evaluation to investigate the efficacy and safety of cyanoacrylate endovenous ablation for varicose veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-05-07

新加坡VenaSeal真实世界上市后评估研究(ASVS)前瞻性纳入100例患者(151条腿,156条主干静脉),于2018年4月至12月接受氰基丙烯酸酯闭合(CAC)治疗静脉曲张。3个月随访显示技术成功率100%,GSV和SSV闭塞率分别为99.3%和100%,生活质量评分显著改善,患者满意度高,术后疼痛低, transient浅表性静脉炎发生率为18%。

要点

  • CAC在亚洲患者中技术成功率100%,3个月GSV闭塞率99.3%、SSV闭塞率100%。
  • 术后3个月rVCSS、EQ-5D、AVVQ和CIVIQ-14评分均较基线显著改善(P < .001)。
  • 79.1%患者极度或非常满意,93%在10天内恢复日常活动,36%恢复工作。

核心结论

  • CAC在亚洲患者早期随访中安全性高,能有效闭合反流的主干静脉。
  • 患者满意度高,术后疼痛低,3个月时生活质量持续显著改善。

研究设计与样本

  • 前瞻性多中心真实世界上市后评估研究(ASVS),在新加坡多种族亚洲人群中开展。
  • 共纳入100例患者(151条腿;156条主干静脉),于2018年4月至12月接受CAC治疗。
  • 151条腿中,49条(32.5%)治疗GSV功能不全,96条(63.6%)治疗双侧GSV功能不全,1条(0.7%)治疗SSV功能不全,5条(3.3%)治疗单侧GSV合并SSV反流。
  • 基线时68条腿(45.0%)为C4-C6病变,67条腿(44.4%)同时接受多点 stab avulsions。
  • 术后2周和12周进行 duplex ultrasound 随访,评估静脉再通(定义为长度≥5 cm)、疼痛评分、rVCSS、EQ-5D、AVVQ、CIVIQ-14及患者满意度,并记录恢复工作和正常活动时间。

主要发现

  • 共59例女性患者,平均年龄60.1 ± 12.7岁。
  • 技术成功率为100%。
  • 患者对手术耐受良好,围手术期疼痛评分低(平均2.9,范围0-9)。
  • 3个月时患者调查显示高满意度:91例中72例(79.1%)极度或非常满意。
  • 10天内,100例中93例(93%)恢复日常活动,36例(36%)恢复工作。

临床怎么用

  • 对于亚洲静脉曲张患者,CAC是一种安全有效的选择,可考虑用于治疗反流的主干静脉。
  • 术后3个月内应随访 duplex ultrasound 评估闭塞率,并关注自限性浅表性静脉炎的发生。
  • CAC术后患者恢复快、疼痛低、满意度高,适合日间手术或快速康复路径。

局限性

  • 仅报告3个月早期结果,长期疗效和安全性有待进一步前瞻性随访。
  • 样本量有限(100例患者),可能影响结果的普遍性。
  • 研究为单国多种族队列,结论外推至其他亚洲人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of A Singapore VenaSeal Real-World Post-Market Evaluation Study (ASVS) was to evaluate the performance of cyanoacrylate closure (CAC) for varicose veins in a prospective multiracial Singaporean Asian cohort. We report early clinical and patient satisfaction outcomes at 3 months after intervention. METHODS: There were 100 patients (151 legs; 156 truncal veins) who underwent CAC between April and December 2018. Of the 151 legs, 49 (32.5%) were treated for great saphenous vein (GSV) incompetence, 96 (63.6%) for bilateral GSV incompetence, 1 (0.7%) for small saphenous vein (SSV) incompetence, and 5 (3.3%) for combined unilateral GSV and SSV reflux. At baseline, 68 legs (45.0%) had C4 to C6 disease, and 67 legs (44.4%) had concomitant multiple stab avulsions. Patients were reviewed at 2 and 12 weeks by duplex ultrasound to check for venous recanalization (defined as ≥5 cm in length), pain score, revised Venous Clinical Severity Score, EuroQol-5 Dimension questionnaire score, Aberdeen Varicose Vein Questionnaire score, 14-item Chronic Venous Insufficiency Questionnaire (CIVIQ-14) for quality of life measures, and patient satisfaction. Time to return to work and normal activities were also recorded. RESULTS: There were 59 female patients, and mean age was 60.1 ± 12.7 years. There was 100% technical success. Patients tolerated the procedure well and reported low periprocedural pain (mean pain score, 2.9 [range, 0-9]). Patient surveys at the 3-month interval showed high satisfaction rates, with 72 of 91 (79.1%) being extremely or very satisfied. By day 10, of 100 patients, 93 (93%) resumed daily activities, whereas 36 (36%) had returned to work. At 2 weeks, GSV and SSV were completely occluded in 150 of 150 (100%) and 6 of 6 (100%) veins, respectively. At 3 months, GSV and SSV occlusion rates were 140 of 141 (99.3%) and 6 of 6 (100%), respectively. Transient superficial phlebitis was reported in 27 of 151 (18 %) legs, which was self-limited. At 3 months, revised Venous Clinical Severity Score improved from 5.00 (range, 1.00-18.00) to 1.00 (0.00-10.00; P < .001); EuroQol-5 Dimension score, from 0.686 (-0.382 to 1.00) to 1.00 (0.12-1.00; P < .001); Aberdeen Varicose Vein Questionnaire score, from 17.14 (1.29-61.15) to 4.83 (0.00-57.12; P < .001); and 14-item Chronic Venous Insufficiency Questionnaire, from 19.64 (1.79-73.21) to 7.14 (0.00-51.79; P < .001). CONCLUSIONS: CAC has a high safety profile and is an effective way to block refluxing truncal veins in Asian patients at early follow-up. Patients are highly satisfied and report low postoperative pain. There is significant continued quality of life improvement at 3 months. Early results are encouraging, but we await further prospective long-term follow-up from the study.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Tang TY, Yap CJQ, Chan SL, et al. Early results of an Asian prospective multicenter VenaSeal real-world postmarket evaluation to investigate the efficacy and safety of cyanoacrylate endovenous ablation for varicose veins. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32387378. doi:10.1016/j.jvsv.2020.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。